“The Danish Health Authority has concluded that the advantages of utilizing the Covid-19 vaccine from Johnson & Johnson don’t outweigh the danger of inflicting the potential adversarial impact, Vaccine-induced Thrombotic Thrombocytopenia (VITT), in those that obtain the vaccine. Therefore, the Danish Health Authority will proceed the Danish mass vaccination programme towards Covid-19 with out the Covid-19 vaccine from Johnson & Johnson,” learn an announcement by Denmark’s well being authority, reported Euronews.
Earlier, Denmark had additionally dropped AstraZeneca’s vaccine over issues of “uncommon” however “severe” side results. The determination was not a simple one to make.
“Taking the current scenario in Denmark under consideration, what we’re at the moment shedding in our effort to stop extreme sickness from Covid-19 can’t outweigh the danger of inflicting potential side results within the type of extreme blood clots in these we vaccinate,” the assertion mentioned.
The well being authority added that the choice “will considerably have an effect on” the vaccination rollout for folks aged between 20 and 39, which shall be delayed by as much as 4 weeks.
“The remaining goal teams will expertise a delay of about one week, as we shall be getting massive quantities of different vaccines,” learn the assertion.
“This determination will, after all, have penalties for many who now have their vaccination postponed. For instance, they must wait longer for the corona passport that so many people are trying ahead to getting. Age is the primary danger issue for extreme sickness from Covid-19, and these are youthful residents who usually are not prone to changing into critically unwell,” it mentioned.
As of May 1, greater than 1.3 million of the nation’s 5.8 million inhabitants had acquired at the least one dose of the vaccine, in accordance with Our World in Data.
The Johnson & Johnson vaccine, generally known as Janssen, in March grew to become the fourth jab to be permitted to be used throughout the European Union by the European Medicines Agency (EMA) after Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna, reported Euronews.
But the American pharmaceutical delayed its deliveries to the 27-member bloc after experiences of significant blood clots emerged within the US the place greater than 6.8 million folks have acquired at the least one shot.
The EMA launched a overview final month however mentioned it remained of the opinion that “the advantages of the vaccine in stopping Covid-19 outweigh the dangers of side results”, reported Euronews.